Key Insights

Highlights

Success Rate

64% trial completion

Published Results

14 trials with published results (47%)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 47/100

Termination Rate

16.7%

5 terminated out of 30 trials

Success Rate

64.3%

-22.3% vs benchmark

Late-Stage Pipeline

7%

2 trials in Phase 3/4

Results Transparency

156%

14 of 9 completed with results

Key Signals

14 with results64% success

Data Visualizations

Phase Distribution

28Total
Not Applicable (3)
Early P 1 (2)
P 1 (7)
P 2 (14)
P 3 (2)

Trial Status

Active Not Recruiting12
Completed9
Terminated5
Recruiting2
Withdrawn1
Unknown1

Trial Success Rate

64.3%

Benchmark: 86.5%

Based on 9 completed trials

Clinical Trials (30)

Showing 20 of 20 trials
NCT02954874Phase 3Active Not Recruiting

Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer

NCT02883062Phase 2Active Not Recruiting

Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer

NCT02276443Not ApplicableActive Not Recruiting

Molecular Testing and Imaging in Improving Response in Patients With Stage I-III Triple-Negative Breast Cancer Receiving Chemotherapy MDACC Breast Moonshot Initiative

NCT01463072Phase 2Active Not Recruiting

Nab-Paclitaxel in Treating Older Patients With Locally Advanced or Metastatic Breast Cancer

NCT02311933Phase 2Active Not Recruiting

Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer

NCT05334069Recruiting

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

NCT03012100Phase 2Active Not Recruiting

Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer

NCT02498613Phase 2Active Not Recruiting

A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors

NCT02079662Not ApplicableActive Not Recruiting

The Role of Lifestyle Factors in Breast Cancer-Related Outcomes

NCT03281902Active Not Recruiting

Genetic Analysis in Blood and Tumor Samples From Patients With Advanced or Metastatic Estrogen Receptor Positive and HER2 Negative Breast Cancer Receiving Palbociclib and Endocrine Therapy

NCT03199885Phase 3Terminated

Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer

NCT01552434Phase 1Terminated

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

NCT02689427Phase 2Completed

Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast Cancer

NCT03317405Phase 1Active Not Recruiting

Phase I Trial of Endoxifen Gel Versus Placebo in Women Undergoing Breast Surgery

NCT02754752Phase 2Active Not Recruiting

Electroacupuncture Therapy in Reducing Chronic Pain in Patients After Breast Cancer Treatment

NCT03101748Phase 1Terminated

Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer

NCT04054557Not ApplicableCompleted

Patient Reported Outcomes, Smart Pill Bottle and Teleheath for Endocrine Therapy Adherence

NCT02593175Phase 2Completed

Women's MoonShot: Neoadjuvant Treatment With PaCT for Patients With Locally Advanced TNBC

NCT03106415Phase 1Completed

Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer

NCT03094052Phase 2Completed

Incidence and Severity of Diarrhea in Patients With HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib

Scroll to load more

Research Network

Activity Timeline